Ampliphi Biosciences Corp (APHB) Sees Significant Decrease in Short Interest

Ampliphi Biosciences Corp (NYSEAMERICAN:APHB) saw a large decline in short interest in the month of December. As of December 29th, there was short interest totalling 851,483 shares, a decline of 4.5% from the December 15th total of 891,694 shares. Approximately 9.1% of the shares of the company are sold short. Based on an average daily volume of 104,314 shares, the short-interest ratio is currently 8.2 days.

Separately, HC Wainwright set a $5.00 target price on Ampliphi Biosciences and gave the stock a “buy” rating in a research report on Monday, October 2nd.

Shares of Ampliphi Biosciences (NYSEAMERICAN APHB) opened at $1.12 on Thursday. The company has a market capitalization of $13.01, a P/E ratio of -0.11 and a beta of 2.93. Ampliphi Biosciences has a 52 week low of $0.67 and a 52 week high of $6.80.

ILLEGAL ACTIVITY WARNING: This piece of content was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright laws. The legal version of this piece of content can be read at https://www.dispatchtribunal.com/2018/01/11/ampliphi-biosciences-corp-aphb-sees-significant-decrease-in-short-interest.html.

About Ampliphi Biosciences

AmpliPhi Biosciences Corporation is a biotechnology company. The Company is focused on the discovery, development and commercialization of phage therapeutics. The Company is engaged in identifying, characterizing and developing naturally occurring bacteriophages with its collaboration partners in bacteriophage biology, synthetic biology and manufacturing, to develop second-generation bacteriophage products.

Receive News & Ratings for Ampliphi Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ampliphi Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply